Skip to main content
JUNS logo

Jupiter Neurosciences, Inc. (JUNS) Stock Price & Analysis

Jupiter Neurosciences, Inc. (JUNS) — MoonshotScore 19/100 (Weak band), calculated Nov 18, 2026. Price $1.46 (-3.95%), as of the Nov 19, 2026 trading session; market cap $1.93M.

Educational signal · not a buy or sell recommendation · How to read this

$1.46 −$0.06 (-3.95%) Market Cap $1.93M

Jupiter Neurosciences, Inc. · JUNS · NASDAQ

Jupiter Neurosciences, Inc. is a clinical-stage pharmaceutical company focused on developing treatments for neuro-inflammation using its resveratrol platform. The company's pipeline includes multiple Phase II trials targeting rare diseases and neurological conditions.

Price as of Nov 19, 2026

Key Statistics

19 of 100

MoonshotScore v2 · Jupiter Neurosciences (JUNS)

Weak
Business Quality Thin (25)
Financial Safety Fragile (5)
Valuation Bubble (1)
Growth Durability Shrinking (3)
Momentum Falling (13)
Why this rating? Method, drivers & history

Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.

  • Business Quality — Is this a genuinely good business?
  • Financial Safety — Could this blow up on me?
  • Valuation — Am I paying a fair price?
  • Growth Durability — Is the growth real and likely to last?
  • Momentum — Is the market already moving on this?
The ten-second read ·

Weak quality, a fragile balance sheet, stalling growth and an expensive valuation, and the price trend has turned against it. The score also carries a risk penalty for a bankruptcy-risk score in the distress zone and losses on top of negative retained earnings. Business Quality: Thin; Financial Safety: Fragile; Valuation: Bubble; Growth Durability: Shrinking; Momentum: Falling.

  • quarterly revenue $24,245 (Q2 FY2026, quarter ended Jun 30, 2026)
  • EPS beat 1 of the last 7 reports

Holding back: weak fundamentals, balance-sheet strain, a rich price, soft growth, weak price trend

What has the MoonshotScore done over time?

MoonshotScore snapshots recorded for JUNS (57 recorded, newest six shown)
RecordedScoreBand
18Weak
18Weak
18Weak
18Weak
19Weak
19Weak

Daily score refresh is delayed. This is the last recorded calculation.

Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.

Computed · How the MoonshotScore is computed →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$1.46
Change on the day-3.95%
52-week range$1.46 – $102.90
Market capitalisation$1.93M—
Shares traded on the day7.7K

Price & events

Other perspectives

Council score for Jupiter Neurosciences (JUNS): perspectives

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

5-Factor Breakdown

Business Quality Weak
Financial Safety Negative
Valuation Negative
Growth Durability Negative
Momentum Negative

Legends Council

4 lenses, 0 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Englander-style lens (simulated) Izzy Englander Favorable read
Klarman-style lens (simulated) Seth Klarman Unfavorable read
Moon AI lens (model) Unfavorable read

Read on: Oct 5, 2026 · older than the 27 hours refresh window; not a current reading

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Weak
Margin of Safety Fairly Valued
Profit Margin Weak
Revenue Growth Weak
Debt/Equity Strong
ROE Strong
Gross Margin Strong

Read on: Oct 5, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

On Oct 5, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.

Readings on this page are from Nov 20, 2026, except a card that shows its own read date.

1 · What is it?

What is Jupiter Neurosciences (JUNS), and what does it report?

Short answer

A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Jupiter Neurosciences, Inc. (JUNS) is listed on NASDAQ. It employs 5 people and is led by Christer Rosen. In Q2 FY2026 it reported revenue of $24,245 and net income of -$2M. The market values it at $1.93M.

2 · Latest results

What do the latest results show for Jupiter Neurosciences (JUNS)?

Short answer · as of

The most recent reported quarter, Q2 FY2026, carried revenue of $24,245. Against analyst estimates the company has EPS beat 1 of the last 7 reports.

Quarterly income statement — 3 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Q2 FY2026$24,245-$2M-$4.08 (diluted)
Q1 FY2026$18,652-$2M-$4.39 (diluted)
Q4 FY2025$21,796-$3M-$5.61 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for Jupiter Neurosciences (JUNS)?

Short answer · as of

What is holding it back is weak fundamentals, balance-sheet strain, a rich price, soft growth, weak price trend. The distress and quality screens read Piotroski F 3. Trailing ratios: current ratio 0.66.

Data-derived red flags

  • Inconsistent delivery — missed Wall Street EPS estimates in 5 of the last 7 reported quarters.
  • Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
5 · Peer comparison

How does Jupiter Neurosciences compare with its peers?

Short answer

Jupiter Neurosciences's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.

Peer set — price, market value and MoonshotScore
CompanyPriceMarket valueScore
Eli Lilly and Company (LLY) Named competitor$1382.75 Nov 18, 2026$1.23T98 5-pillar Nov 18, 2026
Fennec Pharmaceuticals Inc. (FENC) Same industry, near in market value$13.33 Nov 18, 2026$471M91 5-pillar Nov 18, 2026
Zevra Therapeutics, Inc. (ZVRA) Same industry, near in market value$9.07 Nov 19, 2026$540M91 5-pillar Nov 18, 2026
Vertex Pharmaceuticals Incorporated (VRTX) Named competitor$536.45 Nov 18, 2026$136B90 5-pillar Nov 18, 2026
Protalix BioTherapeutics, Inc. (PLX) Same industry, near in market value$3.06 Nov 19, 2026$258M90 5-pillar Nov 18, 2026
Rigel Pharmaceuticals, Inc. (RIGL) Same industry, near in market value$42.53 Nov 18, 2026$801M88 5-pillar Nov 18, 2026
Rallybio Corporation (RLYB) Same industry, near in market value$15.26 Nov 18, 2026$85.5M82 5-pillar Nov 18, 2026
ImmuCell Corporation (ICCC) Same industry, near in market value$11.25 Nov 18, 2026$102M82 5-pillar Nov 18, 2026
Oramed Pharmaceuticals Inc. (ORMP) Same industry, near in market value$3.89 Nov 18, 2026$169M72 5-pillar Nov 18, 2026
Compugen Ltd. (CGEN) Same industry, near in market value$1.88 Nov 19, 2026$178M69 5-pillar Nov 18, 2026
Climb Bio, Inc. (CLYM) Same industry, near in market value$9.28 Nov 19, 2026$545M68 5-pillar Nov 18, 2026
MeiraGTx Holdings plc (MGTX) Same industry, near in market value$8.14 Nov 19, 2026$796M63 5-pillar Nov 18, 2026
Jupiter Neurosciences (JUNS) — this page$1.46$1.93M19

Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.

The records behind this page

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held JUNS in their latest 13F filing, and what they did against the filing before it.

None of the 16 tracked investors reported JUNS in their latest 13F filing.

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What has been published about Jupiter Neurosciences (JUNS)?

Read these with our analysis →

Common Questions About JUNS

These answers are editorial: 1 of these 9 answers is drawn from the JUNS research dossier (written May 10, 2026 by gemini-2.0-flash); the other 8 are question templates that restate figures shown above. Figures in this section are not part of the source register.

What does the MoonshotScore mean for JUNS?

JUNS carries the MoonshotScore stated above — the Weak band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers. Jupiter Neurosciences, Inc. is a clinical-stage pharmaceutical company focused on developing treatments for neuro-inflammation using its resveratrol platform.

Is JUNS a good stock to buy?

Stock Expert AI does not rate JUNS buy, sell or hold. Jupiter Neurosciences, Inc. carries a MoonshotScore, in the Weak band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.

What is the JUNS stock price today?

The last price recorded for Jupiter Neurosciences, Inc. (JUNS), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What are the main risks for JUNS?

The primary risks for Jupiter Neurosciences include the potential failure of its Phase II clinical trials, which would significantly impact the company's valuation and future prospects.

What are the key factors to evaluate for JUNS?

Jupiter Neurosciences, Inc. (JUNS) holds a MoonshotScore in the low range. This growth opportunity is ongoing and dependent on research and development efforts. Not financial advice.

How frequently does JUNS data refresh on this page?

JUNS's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.

What has driven JUNS's recent stock price performance?

Jupiter Neurosciences, Inc. (JUNS) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Focus on neuro-inflammation, a growing area of research interest. See the News tab for the latest drivers. Past performance does not predict future results.

Should investors consider JUNS overvalued or undervalued right now?

Jupiter Neurosciences, Inc. (JUNS) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.

Can I buy fractional shares of JUNS?

Fractional-share availability for Jupiter Neurosciences, Inc. (JUNS) depends on your brokerage, account and supported securities. Check the broker's current eligibility, minimums and fees before placing an order.

Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated May 10, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 15 figures on this page — 7 from Financial Modeling Prep (FMP), 7 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.